Santarus Inc. (SNTS) Initiates Phase IIa Study With SAN-300 In Patients With Active Rheumatoid Arthritis
12/23/2013 9:18:14 AM
SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS) today announced that it has begun patient enrollment in a multicenter, multinational, randomized, double-blind, placebo-controlled, multiple ascending dose study with the investigational drug SAN-300, its novel antibody that inhibits very late antigen-1 (VLA-1; a1ß1 integrin). The Phase IIa study is designed to evaluate the safety and tolerability of repeat subcutaneous (SC) doses of SAN-300 in patients with active rheumatoid arthritis (RA) with inadequate response to disease-modifying anti-rheumatic drugs (DMARDs). Approximately 90 patients will be enrolled in the study.
Help employers find you! Check out all the jobs and post your resume.
comments powered by